Seroreactivity to Human Papillomavirus (HPV) Types 16, 18, or 31 and Risk of Subsequent HPV Infection: Results from a Population-Based Study in Costa Rica

Cancer Epidemiology Biomarkers and Prevention

Volumn 13, Issue 2, 2004, Pages 324-327

  Viscidi, Raphael P ^a,e   Schiffman, Mark ^b   Hildesheim, Allan ^b   Herrero, Rolando ^c   Castle, Philip E ^b   Bratti, Maria C ^c   Rodriguez, Ana Cecilia ^c   Sherman, Mark E ^b   Wang, Sophia ^b   Clayman, Barbara ^a   Burk, Robert D ^d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Proyecto Epidemiologico Guanacaste   (Costa Rica)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ANTIBODY;

ADULT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; COSTA RICA; FEMALE; HUMAN; HUMAN CELL; IMMUNITY; INFECTION RISK; NONHUMAN; POPULATION RESEARCH; PRIORITY JOURNAL; SEROLOGY; SEROTYPE; UTERINE CERVIX; VIRUS INFECTION; VIRUS PARTICLE; WART VIRUS;

ADULT; ANTIBODIES, VIRAL; ANTIBODY FORMATION; COHORT STUDIES; COSTA RICA; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SEROEPIDEMIOLOGIC STUDIES; SEROLOGIC TESTS;

EID: 10744233080     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-03-0166     Document Type: Article

References (14)

1. Ho, G. Y., Bierman, R., Beardsley, L., Chang, C. J., and Burk, R. D. Natural history of cervicovaginal papillomavirus infection in young women. N. Engl. J. Med., 338: 423-428, 1998.
2. Hildesheim, A., Schiffman, M. H., Gravitt, P. E., Glass, A. G., Greer, C. E., Zhang, T., Scott, D. R., Rush, B. B., Lawler, P., and Sherman, M. E. Persistence of type-specific human papillomavirus infection among cytologically normal women. J. Infect. Dis., 169: 235-240, 1994.
3. Viscidi, R. P., Kotloff, K. L., Clayman, B., Russ, K., Shapiro, S., and Shah, K. V. Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women. Clin. Diagn. Lab. Immunol., 4: 122-126, 1997.
4. Herrero, R., Schiffmaa, M. H., Bratti, C., Hildesheim, A., Balmaceda, I., Sherman, M. E., Greenberg, M., Cardenas, F., Gomez, V., Helgesen, K., Morales, J., Hutchinson, M., Mango, L., Alfazo, M., Potischman, N. W., Wacholder, S., Swanson, C., and Brinton, L. A. Design and methods of a population-based natural history study of cervical neoplasia in a rural province of Costa Rica: the Guanacaste Project. Rev. Panam. Salud. Publica., 1: 362-375, 1997.
5. Castle, P. E., Schiffman, M., Gravitt, P. E., Kendall, H., Fishman, S., Dong, H., Hildesheim, A., Herrero, R., Bratti, M. C., Sherman, M. E., Lorincz, A., Schussler, J. E., and Burk, R. D. Comparisons of HPV DNA detection by MY09/11 PCR methods. J. Med. Virol., 68: 417-423, 2002.
6. Viscidi, R. P., Ahdieh-Grant, L., Clayman, B., Fox, K., Massad, L. S., Cu-Uvin, S., Shah, K. V., Anastos, K. M., Squires, K. E., Duerr, A., Jamieson, D. J., Burk, R. D., Klein, R. S., Minkoff, H., Palefsky, J., Strickler, H., Schuman, P., Piessens, E., and Miotti, P. Serum immunoglobulin G response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and risk-matched HIV-negative women. J. Infect. Dis., 187: 194-205, 2003.
7. Ho, G. Y., Studentsov, Y., Hall, C. B., Bierman, R., Beardsley, L., Lempa, M., and Burk, R. D. Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. J. Infect. Dis., 186: 737-742, 2002.
8. Plotkin, S. A. Immunologic correlates of protection induced by vaccination. Pediatr. Infect. Dis. J., 20: 63-75, 2001.
9. Breitburd, F., Kimbauer, R., Hubbert, N. L., Nonnenmacher, B., Trin-Dinh-Desmarquet, C., Orth, G., Schiller, J. T., and Lowy, D. R. Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J. Virol., 69: 3959-3963, 1995.
10. Suzich, J. A., Ghim, S. J., Palmer-Hill, F. J., White, W. I., Tamura, J. K., Bell, J. A., Newsome, J. A., Jenson, A. B., and Schlegel, R. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc. Natl. Acad. Sci. USA, 92: 11553-11557, 1995.
11. Schiller, J. T., and Lowy, D. R. Papillomavirus-like particles and HPV vaccine development. Semin. Cancer Biol., 7: 373-382, 1996.
12. Harro, C. D., Pang, Y. Y., Roden, R. B., Hildesheim, A., Wang, Z., Reynolds, M. J., Mast, T. C., Robinson, R., Murphy, B. R., Karron, R. A., Dillner, J., Schiller, J. T., and Lowy, D. R. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl. Cancer Inst. (Bethesda), 93: 284-292, 2001.
13. Koutsky, L. A., Ault, K. A., Wheeler, C. M., Brown, D. R., Barr, E., Alvarez, F. B., Chiacchierini, L. M., and Jansen, K. U. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J Med., 347: 1645-1651, 2002.
14. Carter, J. J., Koutsky, L. A., Hughes, J. P., Lee, S. K., Kuypers, J., Kiviat, N., and Galloway, D. A. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J. Infect. Dis., 181: 1911-1919, 2000.